Tom 1

Manufactured by Leibniz Institute DSMZ

Sourced in Germany

The TOM-1 is a laboratory instrument designed for the isolation and analysis of total organic matter (TOM) in environmental samples. It operates on the principle of thermal oxidation, providing a rapid and reliable method for quantifying the total organic carbon content of various matrices. The TOM-1 is suitable for use in research, environmental monitoring, and other applications requiring the determination of organic matter levels.

Automatically generated - may contain errors

Lab products found in correlation

8 protocols using tom 1

Characterization of B-cell Leukemia Cell Lines

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

B-ALL cell lines NALM-6, RS4;11, BV-173, REH, TOM-1, NALM-20, SUP-B15, KOPN-8, and EU-3/697, the classical Hodgkin lymphoma (cHL) cell line L428 and Burkitt lymphoma cell line RAMOS, HEK293T, and LentiX cells were purchased from DSMZ (Braunschweig, Germany). The B-ALL cell line 018Z was provided by Meyer L-H., (Ulm University, Germany). Details for the human cell lines used are listed in Supplementary Table 2. Cre-ER^T2 and ER^T2 murine pre-B-cells homozygous for loxP flanked Foxo1 (Foxo1^fl/fl) transformed with BCR-ABL1 were a gift of Jumaa H. (Ulm University, Germany) [7 (link)]. The B-ALL patient-derived xenografts (PDX) JFK125R, PDX2, and BLQ5 were a kind gift of Müschen M. (Yale School of Medicine, USA).

Ketzer F., Abdelrasoul H., Vogel M., Marienfeld R., Müschen M., Jumaa H., Wirth T, & Ushmorov A. (2022). CCND3 is indispensable for the maintenance of B-cell acute lymphoblastic leukemia. Oncogenesis, 11(1), 1.

+ Open protocol

+ Expand

Evaluating Protocols for BCR-ABL+ ALL Treatment

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Sixty-eight BCR-ABL⁺ ALL patients were treated according to European intergroup study of post-induction treatment of Philadelphia chromosome-positive ALL (EsPhALL) 2004 and 2010 protocols (NCT00287105) and ALL-Berlin-Frankfurt-Münster (BFM) 2000 (NCT00430118) study. Informed consent was obtained according to institutional regulations, in accordance with the Declaration of Helsinki. 697, SUP-B15, and TOM-1 cell lines were obtained from DSMZ. Ph⁺ ALL cells containing T315I mutation was kindly provided by Markus Müschen^{38 (link)}.

Abdelrasoul H., Vadakumchery A., Werner M., Lenk L., Khadour A., Young M., El Ayoubi O., Vogiatzi F., Krämer M., Schmid V., Chen Z., Yousafzai Y., Cario G., Schrappe M., Müschen M., Halsey C., Mulaw M.A., Schewe D.M., Hobeika E., Alsadeq A, & Jumaa H. (2020). Synergism between IL7R and CXCR4 drives BCR-ABL induced transformation in Philadelphia chromosome-positive acute lymphoblastic leukemia. Nature Communications, 11, 3194.

+ Open protocol

+ Expand

Cell Line Culturing and Maintenance

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

For full details (age and cytogenetics) please refer to Supplementary Table 2. Reh, NALM-6, RCH-ACV, RS4;11 and TOM-1 were purchased from DSMZ (cat. numbers – ACC 22, ACC 128, ACC 548, ACC 508, ACC 578). K562 were a kind gift from Prof Asim Khwaja, UCL Cancer Institute, Department of Hematology, London, UK. 293T cells were purchased from ATCC (cat. number CRL-3216). All leukemic cells were grown in RPMI 10% FBS at 37 °C and 5% CO₂. 293T cells were grown in DMEM 10% FBS at 37 °C and 5% CO₂. iPSC cells were maintained and differentiated as in ref. 28 (link).

Wray J.P., Deltcheva E.M., Boiers C., Richardson S.Е., Chhetri J.B., Brown J., Gagrica S., Guo Y., Illendula A., Martens J.H., Stunnenberg H.G., Bushweller J.H., Nimmo R, & Enver T. (2022). Regulome analysis in B-acute lymphoblastic leukemia exposes Core Binding Factor addiction as a therapeutic vulnerability. Nature Communications, 13, 7124.

+ Open protocol

+ Expand

Culturing Ph+ Cell Lines for Research

Check if the same lab product or an alternative is used in the 5 most similar protocols

Ph⁺ human cell lines representing myeloid (K562, LAMA‐84, MEG‐A2) or lymphoid (BV173, SUP‐B15, TOM‐1) lineages were purchased from DSMZ. BV173, SUP‐B15, TOM1, K562, and LAMA‐84 cells were maintained in RPMI‐1640 medium (Gibco), supplemented with either 10% (BV173, K562, LAMA‐84) or 20% (TOM1, SUP‐B15) fetal bovine serum (FBS) (HyClone) and 1% penicillin/streptomycin (P/S). MEG‐A2 cells were cultured in Iscove's modified Dulbecco's medium (Gibco), supplemented with 20% FBS (HyClone) and 1% P/S. All cell lines were kept in a humidified atmosphere at 37°C and 5% CO₂ and routinely checked for Mycoplasma contamination.

Komorowski L., Dabkowska A., Madzio J., Pastorczak A., Szczygiel K., Janowska M., Fidyt K., Bielecki M., Hunia J., Bajor M., Stoklosa T., Winiarska M., Patkowska E, & Firczuk M. (2024). Concomitant inhibition of the thioredoxin system and nonhomologous DNA repair potently sensitizes Philadelphia‐positive lymphoid leukemia to tyrosine kinase inhibitors. HemaSphere, 8(3), e56.

+ Open protocol

+ Expand

Pretreatment and Chemotherapy Leukemia Samples

Check if the same lab product or an alternative is used in the 5 most similar protocols

Ethical approval was given (Research Ethics Committee reference 13/LO/1262) for use of appropriately consented material from patients with B-lineage acute lymphoblastic leukemia at Great Ormond Street Hospital for Children (London, UK). Forty-one pretreatment and eight postinduction chemotherapy bone marrow samples were obtained. Pooled normal lymphocyte DNA came from the UK National Blood Service. The leukemic cell lines SUPB15, REH, and TOM-1 were from German Collection of Microorganisms and Cell Cultures (Braunschweig, Germany), and BEL-1 was kindly donated by Dr. R.W. Stam (Erasmus University, Rotterdam, the Netherlands).

Bartram J., Mountjoy E., Brooks T., Hancock J., Williamson H., Wright G., Moppett J., Goulden N, & Hubank M. (2016). Accurate Sample Assignment in a Multiplexed, Ultrasensitive, High-Throughput Sequencing Assay for Minimal Residual Disease. The Journal of molecular diagnostics : JMD, 18(4).

+ Open protocol

+ Expand

Culturing Human ALL Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols

The human ALL cell lines JURKAT, NALM-16, REH, SD-1, SUP-B15, and TOM-1 were obtained from the German Collection of Microorganisms and Cell Cultures (Braunschweig, Germany). Cell lines were cultured in RPMI-1640 medium (Biochrom, Berlin, Germany) supplemented with 1% penicillin/streptomycin (Lonza, Basel, Switzerland) and 10% fetal calf serum (FCS, Biochrom) (JURKAT, NALM-16, SD-1, and TOM-1) or 20% FCS (REH). SUP-B15 cells were cultured in IMDM medium (GIBCO, Carlsbad, CA) with 1% penicillin/streptomycin (Lonza), 1% L-glutamine (Lonza), 1% nonessential amino acids (Lonza), 1% sodium pyruvate (Sigma Aldrich, St. Louis, MO), and 10% FCS. Cells were kept in a humidified atmosphere at 37°C and 5% CO₂.
Mycoplasma contamination was excluded by routine testing of cell lines every 3 months. Cell lines were authenticated by single nucleotide profiling.

Rothfelder K., Hagelstein I., Roerden M., Blumenstock G., Hofmann M., Nuebling T., Jung G., Salih H.R, & Dörfel D. (2018). Expression of the Immune Checkpoint Modulator OX40 in Acute Lymphoblastic Leukemia Is Associated with BCR-ABL Positivity. Neoplasia (New York, N.Y.), 20(11), 1150-1160.

+ Open protocol

+ Expand

Isolation and Culture of PBMCs and B-ALL Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols

All experiments were performed according to the Helsinki protocol and approved by the Ethics Committee of the University of Tübingen (vote: 13/2007V). Informed consent was obtained from all enrolled participants. Peripheral blood samples were collected from healthy donors, and peripheral blood mononuclear cells (PBMCs) were isolated using density gradient centrifugation with Biocoll Cell Separation Solution (Biochrom, Berlin, Germany). The B-ALL cell lines Nalm-6, Nalm-16, SD-1 and TOM-1 were obtained from the German Collection of Microorganisms and Cell Cultures (DSMZ, Braunschweig, Germany) and routinely screened for mycoplasma contamination. PBMCs and cell lines were cultured in RPMI 1640 medium, GlutaMAX Supplement (Life Technologies, Darmstadt, Germany) supplemented with 10% heat-inactivated fetal calf serum (PAN-biotech, Aidenbach, Germany), 100 U/mL penicillin (Sigma-Aldrich, St. Louis, MO, USA) and 100 μg/mL streptomycin (Sigma-Aldrich), at 37 °C with 5% CO₂.

Holzmayer S.J., Kauer J., Mauermann J., Roider T, & Märklin M. (2024). Asciminib Maintains Antibody-Dependent Cellular Cytotoxicity against Leukemic Blasts. Cancers, 16(7), 1288.

+ Open protocol

+ Expand

B-ALL Patient Samples Characterization

Check if the same lab product or an alternative is used in the 5 most similar protocols

Four B-ALL patient samples were obtained from The Pediatric Leukemia Avatar Program within the Cancer & Blood Diseases Institute (CBDI) at Cincinnati Children’s Hospital Medical center, under IRB approval and informed consent. All leukemic specimens contained more than 80% blasts and corresponded to specimens obtained at diagnosis or relapse. Genotyping characterization of these four leukemias had the following monoallelic mutations:
UID 2016-11: BCR/ABL, BCR/EXOSC2, CDKN2A loss, CDKN2B intron 1 truncation;
UID 2017-129: BCR/ABL T315I, CD36 splice site 609+1G>A, SETD2 E282fs*19, SF3B1 T663I (sub), TLL2 G891fs*3, TP53 R248Q.
UID 2018-210: BCR/ABL F359V, T315I, CDKN2A/B loss, IKZF1 loss, MLL2 S2173*, PAX5 Y179fs*64.
UID 2018-132: JAK1 L653 (subclonal) and R724H (subclonal), JAK2 R867Q, IGH/CRLF2, CDKN2A loss exon 1, CDKN2B loss exon 2, FOXP1 R544*, ZRSR2 R448_R449insSRSR.
The B-ALL B-cell progenitors (hCD45^+/low, hCD34⁺, hCD19⁺) cells from these leukemic specimens were sorted and used for confocal immunofluorescence microscopy, western blot and quantitative real time PCR analyses.
Human leukemic cell lines Bv-173, NALM-1, TOM-1, SUP-B15 were obtained from the German Collection of Microorganisms and Cell Cultures (DSMZ; Bv-173, NALM-1 and TOM-1) and American Tissue Culture Collection (ATCC; SUP-B15).

Nayak R.C., Chang K.H., Singh A.K., Kotliar M., Desai M., Wellendorf A.M., Wunderlich M., Bartram J., Mizukawa B., Cuadrado M., Dexheimer P., Barski A., Bustelo X.R., Nassar N.N, & Cancelas J.A. (2022). Nuclear Vav3 is required for polycomb repression complex-1 activity in B-cell lymphoblastic leukemogenesis. Nature Communications, 13, 3056.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!